方盛製藥(603998.SH):擬以1200萬元轉讓2款藥品品種所有權
格隆匯8月2日丨方盛製藥(603998.SH)公佈,2021年8月2日,公司與控股子公司小熊貓藥業簽訂了《藥品上市許可轉讓協議書》,決定以人民幣1200萬元轉讓“小兒複方四維亞鐵散”、“小兒四維葡鈣顆粒”2個藥品品種的所有權。
上述藥品品種所有權包括但不限於該品種的研製原始資料、藥品處方、生產工藝和質量標準、再註冊資料及新藥證書等生產技術和知識產權。
公吿顯示,此次對外轉讓的藥品,近年來銷售總額佔其營業收入總額比重較小,絕對金額不大,且屬於集團內母子公司之間的資源調配,不會對正常生產經營、未來財務狀況和經營成果帶來重大影響。此次藥品轉讓有利於控股子公司小熊貓藥業整合上下游資源,憑藉“上市許可持有人制度”大力推進“生產+銷售”一體化的運營模式進程,提升該次交易藥品未來的市場佔有率,產生更大的經濟效益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.